GPT and metabolic dysfunction-associated steatotic liver disease: Saroglitazar magnesium in patients with nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis (EVIDENCES IV), a phase II clinical study conducted in the USA (NCT03061721), showed that saroglitazar, 4 mg, resulted in significant ALT reduction by 44% from baseline in NAFLD patients.